Caveolin-1 overexpression in benign and malignant salivary gland tumors.
Caveolin-1, a tyrosine-phosphorylated protein, is supposed to have different regulatory roles as promoter or suppressor in many human cancers. However, no published study concerned its expression in benign and malignant salivary gland tumors. The aim of this study was to evaluate and compare the expression of Cav-1 in the most common benign and malignant salivary gland tumors and evaluate its correlation with proliferation activity. In this cross-sectional retrospective study, immunohistochemical expression of caveolin-1 and Ki67 were evaluated in 49 samples, including 11 normal salivary glands, 15 cases of pleomorphic adenoma (PA), 13 adenoid cystic carcinomas (AdCC), and 10 mucoepidermoid carcinomas (MEC). The expression of Cav-1 was seen in 18 % of normal salivary glands and 85 % of tumors. The immunoreaction in the tumors was significantly higher than normal tissues (P = 0.001), but the difference between benign and malignant tumors was not significant (P = 0.07). Expression of Cav-1 was correlated with Ki67 labeling index in PAs, but not in malignant tumors. Cav-1 expression was not in association with tumor size and stage. Overexpression of Cav-1 was found in salivary gland tumors in comparison with normal tissues, but no significant difference was observed between benign and malignant tumors. Cav-1 was inversely correlated with proliferation in PA. Therefore, this marker may participate in tumorigenesis of salivary gland tumors and may be a potential biomarker for cancer treatments.
Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. jaafariz@sums.ac.ir.
Zohreh
Z
Jaafari-Ashkavandi
Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Javad
MJ
Ashraf
Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali Dehghani
AD
Nazhvani
Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra
Z
Azizi
D008949:Adenoma, Pleomorphic / Q000378:metabolism / Q000473:pathology; D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D003528:Carcinoma, Adenoid Cystic / Q000378:metabolism / Q000473:pathology; D018277:Carcinoma, Mucoepidermoid / Q000378:metabolism / Q000473:pathology; D051242:Caveolin 1 / Q000378:metabolism*; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000378:metabolism* / Q000473:pathology; D012469:Salivary Glands / Q000378:metabolism* / Q000473:pathology
D014408:Biomarkers, Tumor; C495540:CAV1 protein, human; D051242:Caveolin 1; D019394:Ki-67 Antigen
Adenoid cystic carcinoma; Caveolin-1; Ki67; Mucoepidermoid carcinoma; Pleomorphic adenoma; Salivary gland tumor